Palvella Therapeutics (PVLA) Other Working Capital Changes (2014 - 2026)

Palvella Therapeutics (PVLA) has 13 years of Other Working Capital Changes data on file, last reported at $357000.0 in Q1 2026.

• On a quarterly basis, Other Working Capital Changes rose 143.59% year-over-year to $357000.0 in Q1 2026; TTM through Mar 2026 was -$188000.0, a 125.47% decrease from a year earlier, with the FY2025 full-year figure at -$1.4 million, down 190.75% from the prior year.
• Other Working Capital Changes for Q1 2026 stood at -$49000.0.
• Over the last five years, Other Working Capital Changes for PVLA reached as high as $19.7 million in Q1 2022 and fell as low as -$47.6 million in Q4 2022.
• Historically, Other Working Capital Changes has averaged -$1.2 million across 5 years, with a median of $134000.0 in 2024.
• Across the five-year window, Other Working Capital Changes soared 3341.02% in 2023 and tumbled 1416.67% in 2025, its largest moves.
• Year by year, Other Working Capital Changes stood at -$47.6 million in 2022, then advanced by 28.37% to -$34.1 million in 2023, then surged by 103.7% to $1.3 million in 2024, then plunged by 117.62% to -$222000.0 in 2025, then surged by 260.81% to $357000.0 in 2026.
• Per Business Quant data, the three most recent Other Working Capital Changes figures were $357000.0 in Q1 2026, -$222000.0 in Q4 2025, and -$182000.0 in Q3 2025.